COVID-19-attributed case and death rates for the U.S.A. were analyzed through May 2020 in three ways – for all 50 states, the country’s largest counties, and the largest counties in California – and found to be statistically significantly higher for states and counties with compared to those without 5G millimeter wave (mmW) technology. 5G mmW index was a statistically significant factor for the higher case and rates in all three analyses, while population density, air quality and latitude were significant for only one or two of the analyses. For state averages, cases per million were 79% higher (p = 0.012), deaths per million were 94% higher (p = 0.049), cases per test were 68% higher (p = 0.003) and deaths per test were 81% higher (p = 0.025) for states with vs. without mmW. For county averages, cases per million were 87% higher (p = 0.005) and deaths per million were 165% higher (p = 0.012) for counties with vs. without mmW. While higher population density contributed to the higher mean case and death rates in the mmW states and counties, exposure to mmW had about the same impact as higher density of mmW states on mean case and death rates and about three times as much impact as higher density for mmW counties on mean case and death rates. Based on multiple linear regression, if there was no mmW exposure, case and death rates would be 18-30% lower for 5G mmW states and 39-57% lower for 5G mmW counties. This assessment clearly shows exposure to 5G mmW technology is statistically significantly associated with higher COVID-19 case and death rates in the U.S.A. The mechanism–should this be a causal relationship–may relate to changes in blood chemistry, oxidative stress, an impaired immune response, an altered cardiovascular and/or neurological response.

The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.

We call for a debate on choices, investigations into grey areas, dialogue on inconsistencies and a transparent model built with citizens for free and informed choices about their health. We call onto the WHO and medical bodies of member countries under the article 1 and article 2 points a, f, g, h, m, p, s of the WHO constitution which are : [1] Article 1 : « The objective of the World Health Organization(hereinafter called theOrganization)shall be the attainment by all peoples of the highest possiblelevel of health » Article 2 : « In order to achieve its objective, the functions of the Organization shall be : - (a) to act as the directing and co-ordinating authority on internationalhealth work - (f) to establish and maintain such administrative and technical services asmay be required, including epidemiological and statistical services - (g)to stimulate and advance work to eradicate epidemic, endemic andother disease - (h) to promote, in cooperation with other specialized agencies where necessary, the prevention of accidental injuries - (m) to foster activities in the field of mental health, especially those affecting the harmony of human relations - (p) to study and report on, in cooperation with other specialized agencieswhere necessary, administrative and social techniques affecting publichealth and medical care from preventive and curative points of view,including hospital services and social security - (s)to establish and revise as necessary international nomenclatures of dis-eases, of causes of death and of public health practices; - (…) » It would appear that these principles have not been respected as demonstrated hereafter.

After several months dealing with capacity-related issues in COVID-19 vaccine administration, US states are set to find themselves with a supply of Pfizer, Moderna, and Johnson & Johnson immunizations outstripping demand for the experimental shots.

By Jim Hoft

The active uptake of exogenous nucleic acids by spermatozoa of virtually all animal species is a well-established phenomenon whose significance has long been underappreciated. A growing body of published data demonstrates that extracellular vesicles released from mammalian somatic tissues pass an RNA-based flow of information to epididymal spermatozoa, thereby crossing the Weismann barrier. That information is delivered to oocytes at fertilization and affects the fate of the developing progeny.

The evidence supporting the reverse transcriptase model of somatic hypermutation is critically reviewed. The model provides a coherent explanation for many apparently unrelated findings. We also show that the somatic hypermutation pattern in the human BCL-6 gene can be interpreted in terms of the reverse transcriptase model and the notion of feedback of somatically mutated sequences to the germline over evolutionary time.

This study shows that we have own-made (endogenous) reverse transcriptase that can influence the properties of blood platelets(thrombocytes) through interaction with their DNA.

2021-04-22. Fakta om covid 19 och vad som måste göras

1. Någon pandemi finns inte Grunden till WHO:s proklamation var PCR-test och prognoser om extremt många sjuka och döda. Ingendera av punkterna är adekvata, någon pandemi i egentlig mening finns sålunda inte.

2. Testerna är missvisande De så kallade PCR-tester som används för diagnos, är oanvändbara för ändamålet. I princip kan alla positiva provsvar vara falska. Denna form av testande måste därför upphöra.

Prion diseases are fatal neurodegenerative conditions with highly accurate CSF and imaging diagnostic tests, but major unmet needs for blood biomarkers. Using ultrasensitive immuno-assays, we measured tau and neurofilament light chain (NfL) protein concentrations in 709 plasma samples taken from 377 individuals with prion disease during a 12 year prospective clinical study, alongside healthy and neurological control groups. This provides an unprecedented opportunity to evaluate their potential as biomarkers. Plasma tau and NfL were increased across all prion disease types. For distinguishing sCJD from control groups including clinically-relevant "CJD mimics", both show considerable diagnostic value. In sCJD, NfL was substantially elevated in every sample tested, including during early disease with minimal functional impairment and in all follow-up samples. Plasma tau was independently associated with rate of clinical progression in sCJD, while plasma NfL showed independent association with severity of functional impairment. In asymptomatic PRNP mutation carriers, plasma NfL was higher on average in samples taken within 2 years of symptom onset than in samples taken earlier. We present biomarker trajectories for nine mutation carriers healthy at enrolment who developed symptoms during follow-up. NfL started to rise as early as 2 years before onset in those with mutations typically associated with more slowly progressive clinical disease. This shows potential for plasma NfL as a "proximity marker", but further work is needed to establish predictive value on an individual basis, and how this varies across different PRNP mutations. We conclude that plasma tau and NfL have potential to fill key unmet needs for biomarkers in prion disease: as a secondary outcome for clinical trials (NfL and tau); for predicting onset in at-risk individuals (NfL); and as an accessible test for earlier identification of patients that may have CJD and require more definitive tests (NfL). Further studies should evaluate their performance directly in these specific roles.